1153380-15-4Relevant academic research and scientific papers
Direct synthesis of a pde4 inhibitor by using pd-cu-catalyzed c-h/c-br coupling of benzoxazole with a heteroaryl bromide
Kuroda, Kiichi,Tsuyumine, Shinjiro,Kodama, Tomohiro
, p. 1053 - 1058 (2016)
A short and practical synthetic route of a PDE4 inhibitor (1) was established by using Pd-Cu-catalyzed C-H/ C-Br coupling of benzoxazole with a heteroaryl bromide. The combination of Pd(OAc)2-Cu(OTf)2-PPh3 was found to be
EP300/CBP Inhibitor
-
Paragraph 0547-0550, (2021/03/31)
The invention discloses an EP300/CBP inhibitor, and particularly provides a compound shown as a formula I, or a deuterated compound, or a salt, or a conformational isomer, or a crystal form, or a solvate thereof. The compound has high selectivity on EP300/CBP, can effectively inhibit the activity of EP300/CBP, and has an excellent inhibition effect on various tumor cells including prostate cancercells, leukemia cells, breast cancer cells and multiple myeloma cells, so that the compound provided by the invention has a wide application prospect in preparation of an EP300/CBP inhibitor, prevention and/or treatment of tumors and malignant diseases of myeloid hematopoietic stem/progenitor cells, and regulation and control of regulatory T cells.
BENZIMIDAZOLONE DERIVATIVES, AND ANALOGUES THEREOF, AS IL-17 MODULATORS
-
Page/Page column 49; 57, (2020/09/03)
A series of substituted benzimidazol-2-one derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune
AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS
-
Page/Page column 64, (2012/04/17)
A compound depicted by the formula below, or a pharmaceutically acceptable salt or solvate thereof. wherein, R1 represents (1) a C3-6 alkyl group,(2) a C1-6 alkyl group substituted with one or more substituent group(s) sel
